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Summary statement 16	
Using a CRISPR screen, we identified important genes that regulate the cell surface 17	
localization of Galectins and clarified the role of the glycosylation in Galectin secretion.  18	
 19	
Abstract  20	
 Galectins are a family of lectin binding proteins expressed both intracellularly and 21	
extracellularly. Galectin-3 (Gal-3) is expressed at the cell surface, however, Gal-3 lacks a 22	
signal sequence and the mechanism of Gal-3 transport to the cell surface remain poorly 23	
understood. Here, using a genome-wide CRISPR/Cas9 forward genetic screen for regulators 24	
of Gal-3 cell surface localization we identified genes encoding glycoproteins, enzymes 25	
involved in N-linked glycosylation, regulators of ER-Golgi trafficking and proteins involved 26	
in immunity. The results of this screening approach lead us to address the controversial role 27	
of N-linked glycosylation in the transport of Gal-3 to the cell surface. We find that N-linked 28	
glycoprotein maturation is not required for Gal-3 transport from the cytosol to the 29	
extracellular space, but is important for cell surface binding. Additionally, secreted Gal-3 is 30	
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predominantly free and not packaged into extracellular vesicles. These data support a 31	
secretion pathway independent of N-linked glycoproteins and extracellular vesicles.  32	
 33	
Introduction  34	
Galectins are an evolutionarily conserved family of β-galactose-binding proteins. 35	
There are 15 members, all of which contain a carbohydrate-recognition domain (CRD). 36	
Family members can be divided into three categories: (i) prototypic single CRD galectins that 37	
can form homodimers; (ii) the galectins that contain two tandem repeat CRDs, and (iii) 38	
galectin-3 which is a chimeric protein containing a single CRD and a disordered N-terminal 39	
region that facilitates oligomerization (Elola, Blidner, Ferragut, Bracalente, & Rabinovich, 40	
2015).  41	
Galectins belong to the leaderless class of proteins (defined by the absence of signal 42	
peptides and transmembrane domains) that function both in the cytoplasm and outside the 43	
cell. Their function in the cytoplasm include roles in cell growth, apoptosis, the cell cycle and 44	
cellular immunity (Boyle & Randow, 2013; Liu & Rabinovich, 2005; Nabi, Shankar, & 45	
Dennis, 2015; Rabinovich, Rubinstein, & Fainboim, 2002). When galectins are outside the 46	
cell, they are known to be retained to the extracellular leaflet of the plasma membrane, 47	
typically through their binding to N-linked glycans and core O-linked glycans on 48	
glycosylated proteins and lipids. From there, they modulate many cellular 49	
processes including endocytosis, migration and adhesion (Elola et al., 2015; Lakshminarayan 50	
et al., 2014; Mazurek et al., 2012; Xin, Dong, & Guo, 2015). In addition, galectins are also 51	
found in the serum where they regulate the activity of immune cells (Rabinovich, Rubinstein 52	
et al. 2002).  53	
Interestingly, Gal-3 is detected at high levels in cardiac patients where it is used as a 54	
marker for cardiovascular disease and heart failure (Jagodzinski et al., 2015; Medvedeva, 55	
Berezin, Surkova, Yaranov, & Shchukin, 2016). Similarly, elevated levels of galectin-1 (Gal-56	
1) are associated with poor prognosis in many cancers including melanoma, lung, bladder and 57	
head cancers (Thijssen, Heusschen, Caers, & Griffioen, 2015). 58	
 The mechanism of galectin secretion remains controversial. As mentioned above, 59	
galectins lack a signal peptide and do not enter the classical ER/Golgi secretory pathway  60	
(Hughes, 1999; Nickel, 2003) and their secretion is not blocked by drugs that inhibit the 61	
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classical secretory pathway such as brefeldin A and monensin (Lindstedt, Apodaca, 62	
Barondes, Mostov, & Leffler, 1993; Sato, Burdett, & Hughes, 1993).  63	
Currently, three major mechanisms have been proposed to explain the unconventional 64	
secretion of leaderless proteins: (i) direct translocation across the plasma membrane either 65	
through a transporter or by auto-transportation as in the case of FGF2; (ii) The engulfment 66	
into extracellular vesicle (exosome and microvesicle), and (iii) the capture into a membrane 67	
bound compartment such as secretory autophagosome, a late endosome or CUPS (Hughes, 68	
1999; Nickel & Rabouille, 2009; Nickel & Seedorf, 2008). 69	
Evidence is lacking for a mechanism involving direct translocation of galectins across 70	
the membrane. In particular, a transporter is yet to be identified and the auto-transportation by 71	
pore formation is also lacking (Hughes, 1999; Nickel & Rabouille, 2009; Nickel & Seedorf, 72	
2008; Rabouille, 2017). Galectin secretion via microvesicles or exosomes, collectively 73	
termed extracellular vesicles (EVs) has been proposed (Cooper & Barondes, 1990; Mehul & 74	
Hughes, 1997; Sato et al., 1993; Seelenmeyer, Stegmayer, & Nickel, 2008). Indeed, Gal-3 75	
and Gal-1 are recruited to the cytoplasmic leaflet of the plasma membrane where they are 76	
secreted in microvesicles generated by plasma membrane budding (Cooper & Barondes, 77	
1990; Mehul & Hughes, 1997). However, contrasting reports show that Gal-1 secretion is not 78	
reduced when plasma membrane blebbing is inhibited (Seelenmeyer et al., 2008). 79	
Furthermore, secretion in EVs does not explain how galectins are subsequently delivered to 80	
the cell surface, although the EVs may be disrupted in the extracellular space to release Gal-3 81	
(Mehul & Hughes, 1997). It has also been proposed that Gal-1 is directly transported across 82	
the plasma membrane while coupled to glycoproteins or lipids on the inner leaflet of the 83	
membrane of the secretory vesicles. Indeed, Gal-1 secretion requires a functional CRD for 84	
cell surface localisation, and binding to glycoproteins proteins or glycolipids may recruit 85	
galectins to the inner leaflet of the plasma membrane and mediate transport across the 86	
membrane to the cell surface (Seelenmeyer et al., 2005). However, Chinese hamster ovary 87	
(CHO) cells lacking the ability to glycosylate glycoproteins efficiently secrete Gal-1 (Cho & 88	
Cummings, 1995), suggesting that the glycans do not play a role in the secretion. Therefore, 89	
not only the mechanism of galectin secretion from the cell remains elusive, but also the role 90	
of glycosylation in the secretion process.  91	
What is better established, however, is that moieties of N-linked glycoproteins and 92	
lipids that are exposed to the extracellular leaflet of the plasma membrane are important for 93	
restricting galectins to the cell surface of cells after their secretion and prevent them to 94	
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diffuse in the extracellular medium. For instance, exogenous purified Gal-1, -3 and -8 only 95	
bind to the cell surface when N-linked glycosylation pathways are intact and N-linked 96	
glycans expressed at the cell surface (Patnaik et al., 2006). 97	
To identify key regulators of Gal-3 cell surface localization (the sum of both its 98	
secretion and its retention) and clarify the role of glycosylation in either, we performed a 99	
genome-wide CRISPR/Cas9 forward genetic screen. The most significantly enriched genes 100	
identified in the screen encodes glycoproteins, enzymes involved in N-linked glycan 101	
maturation and proteins regulating ER-Golgi trafficking. 102	
We focused on the role of two genes identified in the CRISPR screen that encode 103	
proteins essential for N-linked glycosylation. When N-linked glycosylation was disrupted the 104	
level of Gal-3 on the cell surface decreased. This was not due to a disruption of Gal-3 105	
secretion from the cytosol to the extracellular space, as free Gal-3 was detected in the 106	
medium. This demonstrates that N-linked glycosylation is not required for secretion of Gal-3, 107	
but is essential for cell surface binding. These data support a model where N-linked 108	
glycosylation is not required for secretion of Gal-3 to the extracellular space. 109	
Furthermore, we tested the role of EVs in Gal-3 secretion but we conclude that they are not 110	
involved. 111	
 112	
Results  113	
A genome-wide screen identifies genes required for galectin-3 cell surface localization  114	
Due to the limited knowledge about Gal-3 trafficking from the cytosol to the cell 115	
surface and its regulation, we set out to identify genes required for cell surface localization of 116	
Gal-3. At steady state suspension HeLa cells (sHeLa) express Gal-3 on their surface (figure 117	
S1A) and there is a small proportion detectable in the medium (figure S1B). To be found on 118	
the outer leaflet of cell surface, Gal-3 must be secreted from the cytosol through an 119	
unconventional protein trafficking pathway. Therefore, we performed a genome-wide 120	
CRISPR/Cas9 forward genetic screen in sHeLa and enriched for cells with decreased cell 121	
surface Gal-3 (figure 1A). To ensure optimal screening parameters, sHeLa cells stably 122	
expressing Cas9 nuclease (sHeLa-Cas9) were analysed for Gal-3 surface expression by flow 123	
cytometry. Gal-3 surface expression was largely homogenous; however, the small population 124	
of Gal-3 negative cells were removed in a pre-clear cell sort to optimize screening 125	
parameters. The resulting population (approximately 1x108 cells) was then transduced with 126	
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the GeCKO v2 sgRNA library, containing 123,411 guide RNAs targeting 19,050 genes, at a 127	
multiplicity of infection of approximately 0.3 (Shalem et al., 2014; Timms et al., 2016). 128	
Untransduced cells were removed through puromycin selection and rare cells that had 129	
reduced cell surface Gal-3 were enriched by two rounds of fluorescence activated cell sorting 130	
(FACS) (figure 1A and 1B). The sgRNA abundance of the enriched population was 131	
quantified by deep sequencing and compared to the control unsorted population (figure 1C) 132	
(Konig et al., 2007; Timms et al., 2016). Strikingly the most significantly enriched genes 133	
identified in this screen coded for Golgi enzymes involved in N-linked glycosylation or 134	
proteins regulating ER-Golgi transport (figure 1C and D). These include solute carrier family 135	
35 member A2 (SLC35A2), mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-136	
acetylglucosaminyltransferase (MGAT1), mannosidase alpha class 1A member 2 (MAN1A2) 137	
and component of oligomeric Golgi complex 1 (COG1) (figure 1C and 1D and table S1). To 138	
further analyze the function of the genes identified in this screen we applied bioinformatic 139	
pathway analysis to the 200 most enriched genes (Huang da, Sherman, & Lempicki, 2009a, 140	
2009b). This analysis showed that of the genes with known function many genes coded for 141	
glycoproteins such as Integrin Subunit Beta 3 (ITGB3), Laminin Subunit Beta 2 (LAMB2) 142	
and basigin (CD147), or proteins involved in the transport of glycoproteins within the Golgi 143	
and to the cell surface including ADP-ribosylation factor 1 (ARF1) and ADP-ribosylation 144	
factor l Like GTPase 3 (ARL3)  and proteins with roles in immunity including NLR Family 145	
Pyrin Domain Containing 2 (NLRP2) and Tripartite Motif Containing 5 and 34 (TRIM5, 146	
TRIM34) (table 1). Interestingly, several proteins identified in this screen are known Gal-3 147	
interactors either on cell surface such as the integrins, laminins and CD147 or in the cytosol 148	
for the TRIMs (Chauhan et al., 2016; Priglinger et al., 2013).  149	
No core ER proteins or enzymes required for N-linked glycosylation upstream of the 150	
Golgi were identified in the screen. Furthermore, not all subunits of the COG family were 151	
identified. sgRNAs targeting Gal-3 itself were also not enriched in the screen. Analysis of the 152	
control unsorted population shows that the screen was not saturating and 7% of the sgRNA in 153	
the library were not present and around 20% showed a coverage of less than 200 cells/sgRNA 154	
(data not shown). Five sgRNAs targeting Gal-3 were efficiently represented, yet these cells 155	
were not enriched during the screen. This may indicate that these guides were not effective at 156	
targeting Gal-3 or Gal-3 deletion is lethal or decreased cell growth Another explanation for 157	
the lack of Gal-3 sgRNA enrichment is that Gal-3 secreted by other surrounding cells is able 158	
to bind to the surface of Gal-3 null cells, masking the effect of the knockout in our FACS 159	
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assay. This scenario could also affect other knockout cells, where the sgRNA targets key 160	
regulators of Gal-3 secretion but glycosylated binding partners on the cell surface are 161	
unaffected. However, some of the hits identified in the screen such as TRIM34, TRIM5, 162	
ARHGAP30 and ARHGAP9 are not known to regulate the glycosylation pathway. Therefore, 163	
it remains unclear why Gal-3 was not enriched in this screen.   164	
 Additionally, we did not identify genes previously linked to unconventional secretion 165	
such as LC3, GABARAP, GRASP55 and ESCRT components (table S1) (for review, (Nickel 166	
& Rabouille, 2009; Rabouille, 2017). To further confirm that autophagy, the GRASP55 and 167	
the ESCRT pathways do not regulate cell surface localization of Gal-3, we used LC3 and 168	
GABARAP knockout cells (figure S2A), GRASP55 esiRNA (figure S2B) and a Vps4 169	
dominant negative mutant (figure S2C). In all cases the cell surface expression of Gal-3 170	
remained unaffected, further verifying the absence of these genes in the CRISPR/Cas9 171	
forward genetic screen.  172	
 173	
N-linked glycosylation is required for cell surface binding but not galectin secretion  174	
Since it remains controversial whether glycosylation is required for galectin 175	
trafficking to the cell surface, we determined if defective N-linked glycosylation decreased 176	
Gal-3 trafficking to the cell surface or if N-linked glycoproteins are simply required for Gal-3 177	
cell surface binding. Tunicamycin blocks the transfer of N-acetylglucosamine-1-phosphate 178	
from UDP-N-acetylglucosamine to dolichol phosphate, the first step in N-linked 179	
glycosylation (figure 2A) and was used to inhibit glycosylation in sHeLa cells. Cells were 180	
treated with increasing concentrations of tunicamycin to inhibit N-linked glycosylation and 181	
the level of cell surface Gal-3 was assessed by flow cytometry. Cell surface Gal-3 decreased 182	
as the concentration of tunicamycin increased (figure 2B). Propidium iodide was used to 183	
measure cell viability and cells remained viable at all tunicamycin concentrations (figure 2B, 184	
right). In agreement with the results of the CRISPR screen, this shows that a reduction in N-185	
linked glycosylation (and thus complex glycans at the cell surface) decreases cell surface 186	
Gal-3. 187	
To investigate whether N-linked glycosylation is required for transport of Gal-3 from 188	
the cytosol to the extracellular space, the supernatant of sHeLa cells treated with tunicamycin 189	
was analysed by western blotting. In this assay, if N-linked glycosylation is indeed required 190	
for Gal-3 transport there should be a reduction in the level of Gal-3 in the supernatant 191	
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compared to untreated cells. Conversely, if N-linked glycosylation is only required for cell 192	
surface binding and not for secretion, there should be an increase in free Gal-3 measured in 193	
the supernatant. Western blotting showed a concentration dependent increase of Gal-3 in the 194	
supernatant after tunicamycin treatment (figure 2C). A similar trend was observed for Gal-1 195	
(figure 2C, left). The effectiveness of tunicamycin treatment was confirmed by assessing the 196	
relative expression of the ER resident protein BiP (GRP78), where increased expression 197	
indicates ER stress (figure 2C). Actin and Annexin A2 were used as negative controls, with 198	
low levels detectable in the supernatant upon tunicamycin treatment (figure 2C). These 199	
results support the suggestion that Gal-3 and Gal-1 require N-linked glycans to bind to the 200	
cell surface (Patnaik et al., 2006). These data also suggest that secretion of galectins from the 201	
cytosol to the extracellular space is independent of N-linked glycosylation.  202	
 203	
N-linked glycan maturation mediated by MGAT1 and SLC35A2 is required for Gal-3 204	
cell surface binding but not secretion 205	
The use of tunicamycin to block N-linked glycosylation provides proof of principle 206	
but there may be confounding factors due to off target effects. Therefore, to validate the 207	
findings of the CRISPR screen and investigate the role of N-linked glycan maturation we 208	
targeted MGAT1 and SLC35A2; two genes that were highly enriched in the screen and are 209	
known to be specifically required for N-linked glycosylation (figure 1C and 1D). In the cis-210	
Golgi MGAT1 adds N-acetylglucosamine to the sugar backbone of glycoproteins, initiating 211	
complex N-linked glycosylation (figure 1D). SLC35A2 acts later in the trans-Golgi, 212	
transporting UDP-galactose into the trans-Golgi network for addition onto glycoproteins 213	
(figure 1D).  214	
We generated MGAT1 and SLC35A2 CRISPR knockout cell lines using guide RNAs 215	
from an independent CRISPR/Cas9 library (Wang et al., 2015). This provides an additional 216	
control for off-target effects as the guide RNAs differed from those used in our original 217	
CRISPR screen. Single cell cloning, using FACS, was carried out to obtain knockout clones 218	
for MGAT1 and SLC35A2 (figure S3). To evaluate the presence of CRISPR induced 219	
mutations in either MGAT1 or SLC35A2 genes, the targeted region of the gene was 220	
amplified and sequenced. Alignments and Tracking of Indels by Decomposition (TIDE) 221	
analysis confirmed that MGAT1 and SCL35A2 contain CRISPR induced insertions and 222	
deletions (figure S3) (Brinkman, Chen, Amendola, & van Steensel, 2014). MGAT1 and 223	
SLC35A2 clones contained a combination of homozygous and compound heterozygous 224	
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deletions likely to disrupt gene function (figure S3). As a positive control, additional MGAT1 225	
and SLC35A2 clones that expressed cell surface Gal-3 to a similar level as untargeted cells 226	
(Gal-3 positive) were isolated; these contained no insertions or deletions in the targeted 227	
region (figure S3).  228	
CRISPR induced deletions led to a loss of target protein expression in both MGAT1 229	
clones and SLC35A2 clones, assessed by western blotting (figure 3A). MGAT1 and 230	
SLC35A2 protein levels are similar to wild type in the Gal-3 positive clones (figure 3A). 231	
MGAT1 and SLC35A2 are both essential for N-linked glycosylation, so defective 232	
glycosylation would be expected on all N-linked glycoproteins. To assess this, lysosomal 233	
associated membrane protein-2 (LAMP-2) glycoforms were analysed by western blotting. 234	
MGAT1 and SLC35A2 deficient clones expressed a lower molecular weight form of LAMP-235	
2 compared to wild type and Gal-3 positive sHeLa cells (Figure 3A). This indicates that there 236	
are fewer mature N-linked glycans added to LAMP-2 when MGAT1 or SLC35A2 are absent.  237	
To confirm that the loss of MGAT1 and SLC35A2 leads to a decrease in the 238	
expression of Gal-3 on the cell surface, as identified in the initial CRISPR screen, we 239	
assessed cell surface Gal-3 using flow cytometry. Gal-3 positive clones expressing MGAT1 240	
and SLC35A2 were indeed positive for Gal-3 at a comparable level to wild type sHeLa 241	
(figure 3B). Likewise, MGAT1 and SLC35A2 deficient clones obtained from the Gal-3 242	
negative population showed a marked reduction in the expression of Gal-3 (figure 3B). 243	
Therefore, the Gal-3 negative phenotype seen by flow cytometry can be attributed to 244	
CRISPR-mediated knockout of MGAT1 and SLC35A2, further validating the original 245	
CRISPR screen. 246	
To assess whether loss of MGAT1 or SLC35A2 impacts the transport of Gal-3 from 247	
the cytosol to the extracellular space, we analysed Gal-3 secretion by western blotting. Our 248	
results show that in both MGAT1 and SLC35A2 deficient cells, Gal-3 is readily detected in 249	
the extracellular medium (figure 3C). Furthermore, in MGAT1 and SLC35A2 deficient cells 250	
there was an increase in the relative amount of Gal-3 in the supernatant compared to the wild 251	
type sHeLa control (figure 3C). This was not seen in the Gal-3 positive wild type clones, 252	
which remained similar to wild type sHeLa (figure 3C). Gal-1 also showed a similar trend in 253	
SLC35A2 knockout cells (figure S3). Therefore, a lack of N-linked glycosylation due to 254	
MGAT1 or SLC35A2 deficiency leads to reduced galectin binding to the cell surface and an 255	
increase in galectin in the supernatant. This is indicative of a binding defect and not a 256	
reduction in secretion. 257	
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 258	
CHO glycosylation mutants also efficiently secrete galectins  259	
To further assess the role of N-linked glycosylation in the transport of galectins to the 260	
cell surface and their secretion, several well characterized CHO cell lines with glycosylation 261	
defects were used to validate our data (Stanley, 1989). These include an MGAT1 loss of 262	
function mutant (Lec1), an SLC35A2 loss of function mutant (Lec8) and an MGAT1 and 263	
SLC35A2 loss of function double mutant (Lec3.2.8.1) (Stanley, 1989). The aberrations in the 264	
N-linked glycans produced from each cell line are depicted in figure 4A. 265	
These cell lines were previously used to analyze galectin-glycan binding specificity, 266	
demonstrating that N-linked glycans are the major ligand for Gal-1, -3 and -8 binding at the 267	
cell surface	 (Patnaik & Stanley, 2006). These mutant CHO lines were used here to further 268	
assess Gal-3 and Gal-1 cell surface binding and secretion. Flow cytometry analysis of Gal-3 269	
expression on the surface of CHO cells showed that MGAT1 (Lec1) and SLC35A2 (Lec8) 270	
single loss of function mutant lines, as well as the MGAT1/SLC35A2 (Lec3.2.8.1) double 271	
mutant line all exhibited a decrease in the level of Gal-3 detectable on the cell surface 272	
compared to the wild type (Pro5) (figure 4A). This phenotype was reversed in an MGAT1 273	
rescue cell line, confirming that the loss of Gal-3 on the surface is due to the loss of function 274	
mutation in the MGAT1 gene (figure 4B) (Chen & Stanley, 2003; Kumar & Stanley, 1989). 275	
Western blotting analysis showed that Gal-3 was secreted by MGAT1 (Lec1) and SLC35A2 276	
(Lec8) loss of function cells as expected (figure 4C). Furthermore, the level of Gal-3 277	
detectable in the medium is substantially higher than the wild type (Pro5) CHO and MGAT1 278	
rescue cell lines (figure 4C). This was also evident when Gal-1 secretion was assessed (figure 279	
4C). These data are consistent with results obtained in sHeLa lines and further confirms that 280	
N-linked glycosylation is not required for Gal-3 secretion.  281	
 282	
Secreted Gal-3 is primarily free and not packaged into extracellular vesicles  283	
Thus far, we have shown that N-linked glycan maturation is not required for the 284	
transport of Gal-3 from the cytosol to the extracellular space and is a regulatory element that 285	
retains galectins at the cell surface. Next, we set out to investigate whether secreted Gal-3 is 286	
free in the medium or packaged into EVs. There is conflicting data in the literature as to 287	
whether galectins are secreted via EVs (Cooper & Barondes, 1990; Mehul & Hughes, 1997; 288	
Sato et al., 1993; Seelenmeyer et al., 2008). To investigate this, the medium from wild type, 289	
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MGAT1 or SCL35A2 deficient cells was collected and subjected to differential 290	
centrifugation. Briefly, cells were removed at 300g, then the cell debris was removed at 291	
3000g and EVs pelleted at 100,000g. The supernatant and EV pellets were separated after 292	
centrifugation at 100,000g and each assessed for Gal-3 by western blot. The data show 293	
similar levels of Gal-3 in the medium after removing EVs at 100,000g, indicating that the 294	
majority of the secreted Gal-3 is free and not packaged in vesicles (figure 5A and B). Gal-3 is 295	
detectable in the 100,000g EV pellet of all cell lines, although the levels were somewhat 296	
variable, and there was a small increase in the amount of both actin and Gal-3 detected in the 297	
EV pellets from MGAT1 deficient clones (figure 5A and B). It is important to note that the 298	
EV pellets are 50x concentrated compared to the supernatant samples (figure 5A and B). To 299	
assess the composition of the 100,000g pellet further, we analysed the tetraspanin CD63 300	
which is known to be enriched in exosomes (Escola et al., 1998). The 100,000g pellet was 301	
CD63 positive and therefore contained some exosomes (figure 5A and B). Due to impaired 302	
glycosylation CD63 runs as a smaller form in the MGAT1 and SLC35A2 deficient EVs 303	
(figure 5A and B). The lack of glycosylation on CD63 seems to affect the antibody detection 304	
and the naked non-glycosylated form it detected better than the glycosylated form. Therefore, 305	
it is difficult to comment on the relative levels of CD63 in the EV pellets of the MGAT1 and 306	
SLC35A2 compared to the wild type controls. However, we believe that the lack of MGAT1 307	
or SLC35A2 does not affect the formation or level of EVs.  308	
We also assessed whether Gal-3 secreted from CHO MGAT1 (Lec1), SLC35A2 309	
(Lec8) and MGAT1/SLC35A2 double (Lec3.2.8.1) mutant cell lines is also free and not 310	
packaged into EVs. In agreement with the sHeLa MGAT1 and SLC35A2 deficient cells, the 311	
levels of Gal-3 secreted from the CHO MGAT1 (Lec1), SLC35A2 (Lec8) and 312	
MGAT1/SLC35A2 double (Lec3.2.8.1) mutant lines remained unchanged after a 100,000g 313	
centrifugation step (figure 5C). There was a small increase in the level of Gal-3 and actin 314	
detectable in the EV pellets of MGAT1 (Lec1), SLC35A2 (Lec8) and MAGT1/SLC35A2 315	
double (Lec3.2.8.1) mutants compared to wild type (Pro5) and rescue lines (figure 5C). This 316	
may also be reflected in the MGAT1 deficient cells but is not the case for SLC35A2 which 317	
was more variable (figure 5A and B). Therefore, any differences in level of EVs secreted is 318	
trivial and is unlikely to significantly contribute to the levels of secreted Gal-3. Due to 319	
differences in the species of the cells we were unable to evaluate CD63 in the EV pellets of 320	
CHO. Together these results show that Gal-3 associated with EVs comprises a small 321	
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proportion of the total secreted Gal-3 and therefore cannot be the primary route for trafficking 322	
outside the cell.  323	
 324	
 N-linked glycoproteins are required for the recruitment of intracellular Gal-3 to 325	
damaged lysosomal membranes  326	
Gal-3 has important roles in regulating cell death and immunity, and is recruited to 327	
endolysosomes, lysosomes and phagosomes in response to induced organelle damage and 328	
damage due to bacterial infection (Aits et al., 2015; Feeley et al., 2017; Maejima et al., 2013; 329	
Paz et al., 2010). In addition, Gal-3 interacts with TRIM16 to coordinate autophagy to protect 330	
against cell damage and bacterial invasion (Chauhan et al., 2016). Recruitment to lysosomes 331	
or Shigella disrupted phagosomes is dependent on Gal-3 binding to N-linked glycans, as 332	
shown using a Gal-3 CRD mutant and CHO MGAT1 mutant (Lec1) cells respectively (Aits 333	
et al., 2015; Paz et al., 2010). Therefore, N-linked glycans are not only important for cell 334	
surface localisation of Gal-3 but are also central for the recruitment of Gal-3 to damaged 335	
lysosomes. To further characterize our MGAT1 and SLC35A2 deficient sHeLa cell lines, we 336	
assessed the ability of Gal-3 to redistribute from the cytosol to the membrane of leaky 337	
lysosomes (Maejima et al., 2013). To do so we expressed green fluorescent protein (GFP) 338	
fused to Gal-3 in wild type, MGAT1 and SLC35A2 deficient sHeLa lines. All cell lines were 339	
then treated with L-Leucyl-L-Leucine methyl ester (LLOMe) to induce lysosomal leakiness 340	
and we assessed the recruitment of GFP-Gal-3 to the site of damage by immunofluorescence 341	
(Maejima, Takahashi et al. 2013). In wild type cells, GFP-Gal-3 is efficiently redistributed 342	
from the cytosol to the site of lysosomal damage, colocalizing with LAMP-2 positive puncta 343	
(figure 6A). However, in MGAT1 and SLC35A2 deficient cells the recruitment of GFP-Gal-3 344	
to LAMP-2 positive damaged lysosomes are reduced (figure 6A). We also assessed 345	
recruitment of LC3, as damage to lysosomes should initiate autophagy to degrade the 346	
dysfunctional organelle (Maejima et al., 2013). As expected, in wild type cells treated with 347	
LLOMe GFP-Gal-3 positive puncta were also mRFP-LC3 positive (figure 6B). In the 348	
MGAT1 and SLC35A2 deficient cells recruitment of GFP-Gal-3 to mRFP-LC3 positive 349	
damaged lysosomes is impaired (figure 6B). This further confirms that N-linked glycan 350	
maturation is required for the recruitment of Gal-3 to damaged lysosomes and 351	
autophagosomes, essential for cellular homeostasis and defense.  352	
 353	
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Discussion  354	
Cell surface expression of galectins is essential for cellular homeostasis. Despite 355	
having important functions in the extracellular space, the mechanism of galectin secretion 356	
remains unclear. Galectins do not enter the classical secretory pathway, as they do not contain 357	
a signal peptide and their secretion is not affected by drugs that block this pathway (Hughes, 358	
1999). Therefore, they must exit the cell though an unknown unconventional protein 359	
trafficking pathway. Currently there is limited data available to explain the mechanisms of 360	
galectin trafficking from the cytosol to the extracellular space and current theories are 361	
controversial. Here we applied a genome-wide CRISPR screen using the GeCKO v2 library 362	
to identify regulators of Gal-3 cell surface localisation. Following mutagenesis and enriching 363	
for cells with reduced Gal-3 expression at the cell surface, many genes coding for 364	
glycoproteins or proteins required for N-linked glycan maturation were identified. While this 365	
screen returned many important regulators of Gal-3 it is apparent that the screen was not 366	
saturating. As discussed in the results section, sequencing data from the control unsorted 367	
population shows that the screen was not saturating. However, five sgRNAs targeting Gal-3 368	
were efficiently represented in the control unsorted population, yet these cells were not 369	
enriched during sorting. One explanation for this is that there is free Gal-3 in the medium, 370	
secreted by surrounding cells, that binds to the surface of Gal-3 deficient cells masking their 371	
Gal-3 negative phenotype. This could also mask other important hits where secretion of Gal-3 372	
is impaired but glycosylation is normal. Unfortunately, we were not able to assess the levels 373	
of Gal-3 in the medium and therefore do not know if this explains the lack of Gal-3 sgRNA 374	
enrichment. Moreover, there are hits identified in this screen that are not known to regulate 375	
glycosylation (such as TRIM34, TRIM5, ARHGAP30 and ARHGAP9), which should also be 376	
masked in this scenario. Additionally, we did not detect any ER proteins required for 377	
glycosylation, upstream of the Golgi, which is somewhat surprising. Loss of these proteins 378	
may be lethal or decrease cell proliferation. It is also important to note that the most 379	
significantly enriched genes identified by the screen may not be those most important for 380	
mediating Gal-3 surface localisation, it may simply be that they survive well and are 381	
therefore enriched better than others.   382	
Although the screen was not saturating, the results obtained here are consistent with 383	
the literature as Gal-3 is known to bind to N-linked glycans present on the cell surface 384	
(Patnaik et al., 2006). This is also consistent with the notion that Gal-3 requires N-linked 385	
glycans to facilitate trafficking from the cytosol to the cell surface (Seelenmeyer et al., 2005). 386	
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However, this is controversial and it was important to establish whether glycoproteins 387	
carrying N-linked sugar moieties are required for transport of Gal-3 from the cytosol to the 388	
extracellular space. Using tunicamycin and two different MGAT1 and SLC35A2 mutant cell 389	
lines we demonstrate that Gal-3 cell surface binding is dependent on the expression of 390	
complex N-linked glycans, however, Gal-3 is efficiently secreted in the absence of N-linked 391	
glycans. The secretion of both Gal-3 and Gal-1 was unperturbed in the absence of N-linked 392	
glycosylation, clearly demonstrating that their secretion is independent of both the classical 393	
secretory pathway and any pathway requiring complex glycoproteins and lipids for transport.  394	
The role of EVs in galectin secretion has been controversial, with conflicting reports 395	
in the literature (Cooper & Barondes, 1990; Mehul & Hughes, 1997; Sato et al., 1993; 396	
Seelenmeyer et al., 2008). Here, we demonstrate that transport of Gal-3 from the cytosol to 397	
the extracellular space is not primarily mediated by EVs in sHeLa and CHO cell lines. Due to 398	
the increased levels of Gal-3 detectable in the medium, MGAT1 and SLC35A2 deficient cells 399	
provide an excellent system for assessing whether extracellular Gal-3 is packaged into EVs. 400	
Using differential centrifugation, we show that the vast majority of Gal-3 detected in the 401	
medium is free and soluble, indicating Gal-3 is not packaged into extracellular vesicles. 402	
These data support an EV independent pathway for Gal-3 trafficking to the cell surface and 403	
secretion into the extracellular space.  404	
It has previously been shown that Gal-3 is redistributed from the cytosol to 405	
glycoproteins on the luminal membrane of damaged endolysosomes/phagosomes (Aits et al., 406	
2015; Feeley et al., 2017; Maejima et al., 2013; Paz et al., 2010). Once associated with the 407	
membrane of the damaged organelle, Gal-3 stimulates autophagy to clear the threat (Maejima 408	
et al., 2013). Furthermore, it has been shown that Gal-3 is recruited to Shigella containing 409	
phagosomes in wild type CHO cells but not MGAT1 (Lec1) mutant CHO cells (Paz et al., 410	
2010). Given these previous data we tested the MGAT1 and SLC35A2 deficient sHeLa cells 411	
in this context. As expected, Gal-3 recruitment to damaged lysosomes is impaired in the 412	
MGAT1 and SLC35A2 cell lines. These data, shown by us and others, may explain why 413	
people with congenital disorders of glycosylation (CDG) suffer from recurrent infections, 414	
reviewed (Albahri, 2015; Grunewald, Matthijs, & Jaeken, 2002; Monticelli, Ferro, Jaeken, 415	
Dos Reis Ferreira, & Videira, 2016). CDG are rare genetic disorders where glycosylation of 416	
multiple proteins are deficient or defective due to mutations in the glycosylation pathway; 417	
these mutations can occur in COG1, MGAT1 and SLC35A2 genes among many others 418	
(Albahri, 2015; Grunewald et al., 2002). CDG cause a range multiple organ malfunctions, in 419	
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almost all cases the nervous system is affected and symptoms include developmental 420	
disabilities, ataxia hypotonia, hyporeflexia and immunological defects  (Albahri, 2015; 421	
Grunewald et al., 2002; Monticelli et al., 2016). It is becoming increasingly apparent that 422	
patients with immunological defects are more likely to have mutations in resident ER and 423	
Golgi enzymes (Monticelli et al., 2016). Consistent with this, our data and previous data from 424	
Paz and colleagues suggest that patients with certain forms of CDG could have a reduced 425	
ability to sense bacterial or viral entry in the cytosol due to a lack of galectin recruitment to 426	
the site of infection (Paz et al., 2010).  427	
Together these data demonstrate that galectin cell surface binding and secretion are 428	
two distinct events. This is consistent with previous studies, which have shown that Gal-3 429	
secretion is unaffected by disruptions in the secretory pathway (Cho & Cummings, 1995; 430	
Lindstedt et al., 1993; Sato et al., 1993). Exactly which domains or sequences are essential 431	
for mediating galectin secretion are also controversial. It has been shown that the flexible N-432	
terminal domain on Gal-3 is important for secretion, however, this flexible N-terminal 433	
domain is absent in other galectins (Menon & Hughes, 1999). Therefore, if there is a common 434	
unconventional secretory pathway utilized by the galectin family, it would be somewhat 435	
surprising if this was located in the only domain that is not conserved across the galectin 436	
family. In contrast, other studies have found that the CRD is essential for the effective 437	
secretion of Gal-1 (Seelenmeyer et al., 2005). However, in our hands the CRD mutant Gal-3 438	
(R186S), which is unable to bind GlcNAc, did not show any defects in Gal-3 secretion 439	
compared to the wild type (figure S5)(Salomonsson et al., 2010). It is possible that there are 440	
differences in the requirements for secretion between galectin family members, but this 441	
would be very surprising as the galectins are highly similar and common transport 442	
mechanism would be expected. 443	
Regardless of the exact mechanism, it may be expected that galectins are not secreted 444	
via the conventional secretory pathway as their ligand (complex carbohydrates) is a major 445	
component of the lumen of the ER and Golgi. If galectins had to move through the ER and 446	
Golgi they would come into contact with their ligand, bind and potentially interrupt the 447	
movement of other proteins through the secretory pathway. Therefore, having a separate 448	
pathway for trafficking galectins to the cell surface is an excellent way of ensuring that they 449	
only meet their ligands where required.  450	
Finally, hundreds of genetic disorders that result from deficiencies in different 451	
glycosylation pathways have been described, including several neurological diseases such as 452	
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autism, epilepsy and CDG (Freeze, Eklund, Ng, & Patterson, 2015). Additionally, cancer 453	
cells are known to deeply alter the glycosylation pathway inducing hypo- or hyper-454	
glycosylation (Pinho & Reis, 2015). As such, it would be interesting to study whether the 455	
alterations in several signaling pathways described in these diseases are associated with a 456	
dysregulation of cell surface galectins given the important role of galectins in signal 457	
transduction and cell to cell interactions.    458	
 459	
Materials and methods 460	
Cell culture 461	
Suspension HeLa cells were cultured in DMEM D6546 (Molecular Probes) plus 10% fetal 462	
bovine serum (FBS), 2 mM L-glutamine and 100 U ml−1 penicillin/streptomycin in 5% CO2 463	
at 37°C. LC3 and GABARAP knockout HeLa cells were cultured as described (Nguyen et 464	
al., 2016). Lec cells (CHO), obtained from Pamela Stanley (Albert Einstein College of 465	
Medicine), were cultured in MEM alpha, nucleosides (Molecular Probes, 22571038) plus 466	
10% FBS and 100 U ml−1 penicillin/streptomycin in 5% CO2 at 37°C.  467	
 468	
Antibodies and reagents 469	
Antibodies: rat polyclonal anti-Galectin-3 (Biolegend; 125408; WB: 1/2,000), rat polyclonal 470	
anti-Galectin-3 conjugated to Alexa Fluor647 (Biolegend; 125402; FC: 1/100), rabbit 471	
polyclonal anti-Galectin-1 (a generous gift from Walter Nickel, Heidelberg University; WB: 472	
1/500), mouse monoclonal anti-Annexin A2 (BD Biosciences; 610071; WB: 1/1,000), rabbit 473	
polyclonal anti-Actin (Sigma; A2066; WB: 1/2,000), rabbit polyclonal anti-BiP (Abcam; 474	
ab21685: WB: 1/1,000), mouse monoclonal anti-LAMP2 (Biolegend; 354302; WB: 1/1,000; 475	
IF: 1/100), rabbit polyclonal anti-SLC35A2 (Cambridge Bioscience; HPA036087; WB: 476	
1/500), rabbit polyclonal anti-MGAT1 (Abcam; ab180578; WB: 1/1,000), mouse monoclonal 477	
anti-human CD63 (Thermo Fisher Scientific; 10628D; WB: 1:500), rabbit polyclonal anti-478	
GFP (Clontech; 632592; WB: 1/2,000), rabbit polyclonal anti-LC3B (Novus Biologicals; 479	
NB100-2220; WB: 1/2,000), rabbit polyclonal anti-GABARAP (Abgent; AP1821a; WB: 480	
1/1,000), monoclonal anti-CD29 (BD Biosciences; Clone 18/CD29; WB: 1/2,000) and rabbit 481	
polyclonal anti-GRASP55 (Proteintech; 10598-1-AP; WB: 1/1,000). 482	
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Reagents: tunicamycin (New England Biolabs; 12819), L-Leucyl-L-leucine methyl ester 483	
(Sigma-Aldrich; L7393), propidium iodide solution (Biolegend; 421301), QuickExtract DNA 484	
extraction solution (Epicenter; QE0905T), Herculase II fusion DNA polymerase (Agilent; 485	
600675). Oligonucleotides for MGAT1 and SLC35A2 CRISPR targeting and sequencing 486	
were synthesized from Sigma-Aldrich (table S2). MISSION esiRNA against GRASP55 was 487	
from Sigma-Aldrich (EHU056901).  488	
 489	
Plasmids 490	
pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid # 48138), 491	
Galectin-3 vector, pEGFP-hGal3, and mRFP-LC3 were a gift from Tamotsu Yoshimori 492	
(Addgene plasmid # 73080 and # 21075 respectively) (Maejima et al., 2013), LentiCas9-493	
Blast was a gift from Feng Zhang (Addgene plasmid # 52962), Vps4 wild type and EQ 494	
mutant were a gift from Colin Crump (Crump, Yates, & Minson, 2007).  495	
 496	
CRISPR screen 497	
The Cas9 nuclease was stably expressed in suspension HeLa cells by lentiviral transduction 498	
(Sanjana, Shalem, & Zhang, 2014). Approximately 1x108 cells were then transduced with the 499	
GeCKO v2 sgRNA library (Addgene cat#1000000047, kindly deposited by Prof. Feng Zhang 500	
(Shalem et al., 2014)) at a multiplicity of infection of around 0.2. Untransduced cells were 501	
removed from the library through puromycin selection (1 mg ml-1) commencing 48 h after 502	
transduction. Rare cells that had lost cell surface Galectin-3 were then enriched by sequential 503	
rounds of FACS, with the first sort taking place 7 days after transduction with the sgRNA 504	
library and the second sort a further 14 days later. Genomic DNA was extracted (Puregene 505	
Core Kit A, Qiagen) from both the sorted cells and an unselected pool of mutagenized cells. 506	
sgRNA sequences were amplified by two rounds of PCR, with the second round primers 507	
containing the necessary adaptors for Illumina sequencing (table S2). Sequencing was carried 508	
out using a 50 bp single-end read on an Illumina HiSeq2500 instrument using a custom 509	
primer binding immediately upstream of the 20 bp variable segment of the sgRNA. The 3’ 510	
end of the resulting reads were trimmed of the constant portion of the sgRNA, and then 511	
mapped to an index of all of the sgRNA sequences in the GeCKO v2 library using Bowtie 2. 512	
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The resulting sgRNA count tables were then analyzed using the RSA algorithm using the 513	
default settings (Rivest, Shamir, & Adleman, 1978).  514	
 515	
Bioinformatics pathway analysis  516	
The first 200 hits identified in the CRISPR screen were loaded to the analysis wizard of the 517	
DAVID Bioinformatics Resources 6.8 to perform a pathway analysis (Huang da et al., 2009a, 518	
2009b). According to the algorithm only those genes with known function are included in the 519	
pathway analysis and hence not all genes will appear in the tabulated results (table 1).  520	
 521	
CRISPR-mediated gene disruption 522	
For CRISPR/Cas9-mediated gene disruption, oligonucleotides (Sigma-Aldrich; table S2) for 523	
top and bottom strands of the sgRNA were annealed, and then cloned into the Cas9 524	
expression vector pSpCas9(BB)-2A-GFP (PX458) (Addgene plasmid # 48138, kindly 525	
deposited by Feng Zhang) as previously described	 (Ran et al., 2013). Transfected cells were 526	
sorted for GFP fluorescence and clones were isolated by FACS based on a loss of cell surface 527	
Galectin-3. Gene disruption was verified by collecting genomic DNA from clonal lines with 528	
QuickExtract DNA extraction solution and amplifying the CRISPR/Cas9 targeted region with 529	
primers flanking at least 200 base pairs either side of the expected cut site (table S2).  PCR 530	
products were sequenced by Sanger sequencing. Insertions and deletions analysed by 531	
sequence alignment and Tracking of Indels by DEcomposition (TIDE) (Brinkman et al., 532	
2014). In addition to using the TIDE web tool, the R code was kindly provided by Prof van 533	
Steensel, to analyse clones containing deletions larger than 50 base pairs.  534	
 535	
Flow cytometry 536	
Cells were washed once with serum-free medium, incubated at 4°C for 30 min with an anti-537	
Galectin-3 antibody conjugated to Alexa Fluor647, washed again and analysed on a 538	
FACSCalibur (BD) equipped with lasers providing 488nm and 633nm excitation sources. 539	
Alexa Fluor647 Fluorescence was detected in FL4 detector (661/16 BP). For sorting, cells 540	
were immunostained as above and FACS was carried on an Influx cell sorter (BD) or Aria-541	
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Fusions (BD) equipped with lasers providing 488 nm and 640 nm excitation sources. Alexa 542	
Fluor647 Fluorescence was detected in 670/30 BP detector on Influx and the Aria Fusion.  543	
 544	
Fluorescence and immunofluorescence microscopy 545	
For immunofluorescence microscopy, cells were cultured on coverslips, fixed with 4% 546	
paraformaldehyde in PBS for 5 min and permeabilized with 0.1% Triton X100 in PBS for 547	
5 min. Coverslips were incubated with primary antibodies for 2 h, washed three times with 548	
PBS, and incubated with secondary antibodies for 30 min. Samples were mounted using 549	
ProLong Gold antifade reagent with DAPI (4,6-diamidino-2-phenylindole; Invitrogen) and 550	
observed using a Leica SP8 laser confocal microscope.  551	
 552	
Immunoblotting 553	
All samples were resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and 554	
transferred to polyvinylidene difluoride membranes for blotting. Membranes were blocked 555	
with 5% (w/v) skim milk powder in PBS containing 0.1% Tween-20 (PBS-Tween) for 30 556	
min at room temperature. Membranes were then probed with an appropriate dilution of 557	
primary antibody overnight at 4°C. Membranes were washed three times in PBS-Tween 558	
before incubation in diluted secondary antibody for 1 h at room temperature. Membranes 559	
were washed as before and developed with ECL (Amersham ECL Western Blotting 560	
Detection Reagent RPN2106 for the detection of proteins in the cell lysates or Cyanagen, 561	
Westar XLS100 for the detection of proteins in the secreted fractions) using a Bio Rad Chemi 562	
Doc XRS system. Membranes were stripped with Restore plus (ThermoFisher Scientific, 563	
46430) as per manufactures’ instructions.  564	
 565	
Secretion assay 566	
To measure the secretion of galectins, cells were washed with serum-free medium and 567	
incubated for 24 h for sHeLa or 48 h for CHO (Lec). For sHeLa, serum-free medium was 568	
DMEM plus 2 mM L-Glutamine. For CHO (Lec), serum-free medium was EX-CELL® 325 569	
PF CHO (Sigma-Aldrich, C985Z18). Cell supernatants were then collected, centrifuged at 570	
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300g to remove potential remaining cells, either filtered at 0.22 µm or centrifuged at 3000 g 571	
to remove cell debris, mixed with sample buffer (50 mM Tris-HCl pH 6.8,	 2% SDS (w/v),	572	
0.1% Bromophenol Blue, 10% Glycerol and 100 mM DTT) and boiled at 100˚C for 5 min. 573	
Cell pellets were lysed in lysis buffer (20 mM Tris-HCl pH 6.8,	137 mM NaCl, 1 mM EDTA, 574	
1% Triton X-100 and 10% Glycerol) at 4˚C for 10 min, insoluble material removed by 575	
centrifugation at 10,000 g for 10 min 4˚C. Sample buffer was added and cell lysate were 576	
samples boiled added (as above). Cell lysates and cell supernatants were then subjected to 577	
SDS-PAGE. Densitometry was performed in Image J and the difference in the levels of 578	
secreted Gal-3 were calculated in each cell line using the following equation: (Gal-3 in 579	
supernatant/Gal-3 in lysate). These values were then used to calculate the fold change relative 580	
to the control cells.  581	
 582	
Removal of extracellular vesicles 583	
Cells were processed as described for the secretion assay except after the 3,000g 584	
centrifugation step the medium was collected and centrifuged at 100,000g for 60 min at 4˚C. 585	
After each centrifugation step a sample of the medium was collected for western blotting. 586	
The extracellular vesicle pellet was resuspended in a small volume of non-reducing sample 587	
buffer (50 mM Tris-HCl pH 6.8,	 2% SDS (w/v),	 0.1% Bromophenol Blue, and 10% 588	
Glycerol). Half of the EV pellet sample was taken and DTT added to achieve a final 589	
concentration of 100 mM. All samples were boiled and resolved by SDS-PAGE. The entire 590	
concentrated EV pellet sample was loaded on two gels (reduced and non-reduced) for each 591	
sample due to the small scale of the assay. Therefore the EV pellet is 50x more concentrated 592	
than the equivalent supernatant.  593	
 594	
Statistical analysis 595	
Significance levels for comparisons between groups were determined with a two sample 596	
Students t- test.  597	
 598	
 599	
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 764	
Figure legends 765	
Figure 1.	 A CRISPR/Cas9-mediated genetic screen identifies genes required for cell 766	
surface localization of Gal-3.  767	
A. Schematic view of the CRISPR/Cas9 screen in suspension HeLa (sHeLa) cells to identify 768	
genes required for Gal-3 cell surface localisation. Cells were transduced with a lentiviral 769	
sgRNA library (sgRNA transduction indicated by colors in the nucleus) and cells that were 770	
successfully transduced were selected for with puromycin. After selection, the population 771	
was split into two, one half was sorted by FACS to enrich for cells that have less Gal-3 on the 772	
surface (Gal-3 is represented by small orange shapes on the cell surface) and the other was 773	
not sorted to represent the entire library. After two rounds of enrichment, the DNA from both 774	
the enriched population and the unsorted library was harvested and enriched sgRNAs were 775	
identified by sequencing. Targeted genes were then plotted according to their relative 776	
enrichment.  777	
B. CRISPR-mediated mutagenesis was performed on sHeLa cells using the GeCKO v2 778	
sgRNA library, and rare cells with decreased surface Gal-3 expression were selected by two 779	
	 24	
sequential rounds of FACS. Cell surface Gal-3 was measured on live cells using an anti-Gal-780	
3 antibody conjugated to Alexa Fluor647.  781	
C. Plot illustrating the hits from the CRISPR screen. The RSA algorithm was used to identify 782	
the significantly enriched genes targeted in the selected cells. The most significantly enriched 783	
genes are labelled.  784	
D. Schematic view of the N-linked glycosylation pathway within the Golgi. Genes identified 785	
to be important for Gal-3 surface localisation by the CRISPR screen are highlighted in red, 786	
and those chosen for further study (MAGT1 and SLC35A2) are shown in bold.   787	
	788	
Figure 2.	Tunicamycin decreases cell surface Gal-3 while increasing the level of Gal-3 in 789	
the medium.  790	
A. Schematic representation of tunicamycin inhibition of N-linked glycosylation. 791	
Tunicamycin blocks the transfer of N-acetylglucosamine-1-phosphate from UPD-N-792	
acetylglucosamine to dolichol phosphate, the first step in N-linked glycosylation. 793	
B. Tunicamycin reduces cell surface localization of Gal-3. sHela cells were treated with 794	
increasing concentrations of tunicamycin diluted in serum-free medium for 24 h. Cell surface 795	
Gal-3 was measured on live cells using an anti-Gal-3 antibody conjugated to Alexa Fluor647, 796	
cell viability was also assessed by flow cytometry using propidium iodide. Unstained cells 797	
are shown in grey. Quantification is shown on the right. Error bars represent ±s.e.m. from 798	
biological replicates (n = 3); * p<0.05 using a two sample Students t- test comparing each 799	
tunicamycin concentration to untreated cells. 800	
C. Tunicamycin increases the levels of Gal-3 in the culture supernatant. Western blotting 801	
analysis of cell lysates and supernatants of sHeLa cells treated with increasing concentrations 802	
of tunicamycin (24 h at 37°C in serum-free medium). Note that the tunicamycin treatment 803	
was efficient as seen by increased level of BiP and decreased level of CD29. Quantification is 804	
shown on the right. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 805	
using a two sample Students t- test comparing each tunicamycin concentration to untreated 806	
cells. 807	
 808	
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Figure 3.	MGAT1 and SLC35A2 knockout abrogates Gal-3 cell surface binding but not 809	
secretion.  810	
A. Western blotting analysis of MGAT1 and SLC35A2 deficient sHeLa. Cell lysates were 811	
assessed for either MGAT1 or SLC35A2 protein levels after CRISPR/Cas9 targeting and 812	
single cell cloning based on Gal-3 surface expression. Lysosomal associated protein 2 813	
(LAMP2) was also assessed to analyse defects in glycosylation and actin was used as a 814	
loading control.  815	
B. Cell surface localization of Gal-3 is decreased in MGAT1 and SLC35A2 deficient 816	
suspension HeLa cells measured by flow cytometry. Cell surface Gal-3 was measured on live 817	
cells using an anti-Gal-3 antibody conjugated to Alexa Fluor647. Gray line: no antibody; 818	
black: untransfected; pink: sgMGAT1 positive clone; blue: sgMGAT1 negative clone 1; 819	
green: sgMGAT1 negative clone 2. The same respective colours are used for sgSLC35A2 in 820	
the lower panels. 821	
C. Gal-3 is secreted from MGAT1 and SLC35A2 deficient sHeLa cells. Wild type, positive 822	
control and negative clones for MGAT1 (left) and SLC35A2 (right) cells were incubated in 823	
serum-free medium for 24 h and the cells and medium then assessed by western blot. Gal-3 824	
was assessed in the lysate and medium (supernatant), actin was used as a loading control and 825	
control for cell lysis. Exposure times are indicated to allow relative comparisons between 826	
blots to illustrate the large increase in Gal-3 in the supernatant compared to actin. 827	
Quantification for MGAT1 (right; green) and SLC35A2 (left; orange) is shown at the bottom. 828	
Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample 829	
Students t- test comparing each cell line to wild type cells. 830	
 831	
Figure 4.	MGAT1 and SLC35A2 mutation in CHO Lec cells reduces Gal-3 cell surface 832	
binding but does not affect secretion.  833	
A. Gal-3 cell surface localization is decreased in MGAT1 and SLC35A2 mutant CHO lines. 834	
Cell surface Gal-3 was measured on live MGAT1 (Lec1), SLC35A2 (Lec8) and double 835	
mutant (Lec3.2.1.8) CHO Lec cells compared to wild type (Pro5) cells by flow cytometry 836	
using an anti-Gal-3 antibody conjugated to Alexa Fluor647. Gray line: no antibody; dark 837	
brown: wild type; red: mutants. Predicted N-linked glycans for each cell line are shown on 838	
the histograms. Sugar symbols: purple triangle, fuctose; green circle, mannose; orange circle, 839	
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galactose; blue square, N-acetylglucosamine; pink trapezoid, sialic acid. Quantification is 840	
shown on the right. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 841	
using a two sample Students t- test comparing each mutant CHO line to wild type (Pro5) 842	
cells. 843	
B. Gal-3 cell surface localization is rescued in MGAT1 rescue CHO Lec cells measured by 844	
flow cytometry. Gal-3 was measured as per A. Gray line: no antibody; dark brown: wildtype; 845	
red: mutants; purple: rescue. Quantification is shown on the right. Error bars represent 846	
±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample Students t- test 847	
comparing the MGAT1 mutant and rescue lines to wild type (Pro5) cells. 848	
C. Gal-3 is secreted from MGAT1 and SLC35A2 mutant CHO Lec cells. Wild type (Pro5), 849	
MGAT1 (Lec1), MGAT1 rescue, SLC35A2 mutant (Lec8) and the double mutant 850	
(Lec3.2.8.1) were incubated in EX-CELL® 325 PF CHO for 48 h and cells and medium were 851	
assessed by western blot. Gal-3, Gal-1 and actin were analysed in the cell lysates and medium 852	
(supernatant). Exposure times are indicated to allow the lysates and supernatants to be 853	
compared. Quantification is shown on the right. Error bars represent ±s.e.m. from biological 854	
replicates (n = 3); * p<0.05 using a two sample Students t- test comparing each mutant CHO 855	
cell line to wild type (Pro5) cells. 856	
 857	
Figure 5. Secreted Gal-3 is predominantly soluble and not packaged in extracellular 858	
vesicles.  859	
A. Soluble Gal-3 is secreted from MGAT1 deficient sHeLa cells. Wild type, positive control 860	
and negative clones for MGAT1 deficient cells were incubated in serum-free medium for 24 861	
h. The cells were collected and lysed whereas the medium was subjected to differential 862	
centrifugation at 300g, 3000g and 100,000g. A sample of the medium was collected after 863	
each centrifugation step. Gal-3 was assessed in the lysate, the entire 100,000g EV pellet and 864	
medium (supernatant). Actin was used as a loading control and control for cell lysis. 865	
Exposure times are indicated for comparison. The 100,000g EV pellets were also analysed by 866	
western blot for levels of glycosylated and non-glycosylated CD63. 867	
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B. Soluble Gal-3 is secreted from SLC35A2 deficient sHeLa cells. Wild type, positive control 868	
and negative clones for SLC35A2 deficient cells were incubated in serum-free medium for 24 869	
h. Samples were treated as described in panel A. 870	
C. Secreted Gal-3 from MGAT1 and SLC35A2 mutant CHO Lec cells is soluble. Wild type 871	
(Pro5), MGAT1 (Lec1), MGAT1 rescue, SLC35A2 mutant (Lec8) and the double mutant 872	
(Lec3.2.8.1) were incubated in EX-CELL® 325 PF CHO for 48 h and cells and medium 873	
collected. The cells, 100,000g EV pellet and medium were processed as in A above. Gal-3 874	
and actin were analysed by western blot and exposure times are indicated for comparison. 875	
CD63 was not analysed in this experiment as it does not cross-react with hamster CD63. 876	
 877	
Figure 6.	 Recruitment of GFP-Gal3 to damaged lysosomes is reduced in MGAT1 and 878	
SLC35A2 deficient cells.  879	
A. Wild type (control), MGAT1 deficient (clone 1) or SLC35A2 deficient (clone 1) sHeLa 880	
transiently expressing GFP-Gal-3 for 24 h were treated with 1 mM L-Leucyl-L-Leucine 881	
methyl ester (LLOMe) for 3 h. Cells were fixed with PFA, permeabilised with Triton X100 882	
and subjected to immunocytochemistry using an anti-LAMP2 antibody, then processed to 883	
confocal microscopy. Bars: 10 um. The intensity of LAMP2 and Gal-3 signals measured 884	
using ImageJ in a minimum of 20 cells per condition is shown on the right.  885	
B. Wild type (control), MGAT1 deficient (cl1) or SLC35A2 deficient (cl1) sHeLa transiently 886	
expressing GFP-Gal-3 and mRFP-LC3 for 24 h were treated with 1 mM LLOMe for 3 h. 887	
Cells were fixed with methanol and processed to confocal microscopy. Bars: 10 um. 888	
Colocalization (Pearson’s coefficient) between Gal-3 and LC3 is shown on the right. Error 889	
bars represent ±s.e.m. from individual cells (n > 20); * p<0.05 using a two sample Students t- 890	
test. 891	
 892	
 893	
 894	
 895	
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Category  Count 
Glycoproteins 
ADAM10, ABCC3, CD302, CD33, FRAS1, NDST2, NHLRC3, APLP2, ARTN, CTNND2, CLCA1, CHRM4, C2, 
DSG3, FAP, FGF17, GABRA1, GIF, HS6ST2, HIST1H2BD, ITGB3, IL17D, LAMB2, LUM, MAN1A2, MPZL3, 
NPR1, OLFML2A, OR2S2, OR51B6, OR51G2, PHYHIP, PRL, PCDHB6, SLC36A4, SLC39A9, SLC6A7, SUSD3, 
TOR1a, TMED10 
40 
Golgi apparatus/Golgi membrane 
ADAM10, ARF1, ARL3, NDST2, COL4A3BP, COG1, COG3, COG5, MAN1A2, MGAT1, PACS1, SAR1A, 
SLC35A2, TMED10, TMEM165, UNC50 
16 
Cell junction 
ARF1, KIAA1462, CTNND2, CHRM4, DSG3, DLG2, FAP, GABRA1, ITGB3, TOR1A 
10 
Protein transport 
ARF1, ARL3, COG1, COG3, COG5, NXT2, SAR1A, TMED10, UNC50 
9 
Cell adhesion 
CD33, KIAA1462, CTNND2, DSG3, FAP, ITGB3, LAMB2, MPZL3, PCDHB6 
9 
Immunity 
NLRP2, TIRAP, C2, DCSTAMP, LRMP, MAP3K5, TRIM5 
7 
Protein phosphorylation 
ADAM10, COL4A3BP, DGUOK, MAP3K5, NPR1, OOEP, STK38 
7 
GTPase activation 
DEPDC5, ELMOD2, RAP1GDS1, ARHGAP30, ARHGAP9, TBC1D22A 
6 
Congenital disorders of glycosylation 
COG1, COG5, SLC35A2, TMEM165 
4 
 896	
Table 1. Pathway analysis of the 200 most significantly enriched genes identified in the 897	
genome-wide CRISPR screen for Gal-3 cell surface localisation. 898	













